title: Biosimilars-why terminology matters.
authors.forename: Martina
authors.initials: M
authors.lastname: Weise
authors.forename: Marie-Christine
authors.initials: MC
authors.lastname: Bielsky
authors.forename: Karen
authors.initials: K
authors.lastname: De Smet
authors.forename: Falk
authors.initials: F
authors.lastname: Ehmann
authors.forename: Niklas
authors.initials: N
authors.lastname: Ekman
authors.forename: Gopalan
authors.initials: G
authors.lastname: Narayanan
authors.forename: Hans-Karl
authors.initials: HK
authors.lastname: Heim
authors.forename: Esa
authors.initials: E
authors.lastname: Heinonen
authors.forename: Kowid
authors.initials: K
authors.lastname: Ho
authors.forename: Robin
authors.initials: R
authors.lastname: Thorpe
authors.forename: Camille
authors.initials: C
authors.lastname: Vleminckx
authors.forename: Meenu
authors.initials: M
authors.lastname: Wadhwa
authors.forename: Christian K
authors.initials: CK
authors.lastname: Schneider
mesh_terms: D059451:Biosimilar Pharmaceuticals / Q000592:standards*; D002986:Clinical Trials as Topic; D017277:Drug Approval; D006801:Humans; D009626:Terminology as Topic; D013810:Therapeutic Equivalency
chemical_list: D059451:Biosimilar Pharmaceuticals